QUEENSBURY, N.Y.--(BUSINESS WIRE)--AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it has completed the acquisition of Oncobionic pursuant to the terms of the definitive agreement entered on October 12, 2006. The closing of the acquisition comes as a result of successful initial use of Oncobionic’s irreversible electroporation (IRE) technology in the first human clinical trial for the treatment of soft tissue, conducted during the first week of April 2008.
